These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9813550)

  • 1. Diabetes and coronary artery disease: time to stop taking the tablets?
    Connaughton M; Webber J
    Heart; 1998 Aug; 80(2):108-9. PubMed ID: 9813550
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes, coronary heart disease and sulphonylureas-not the final word.
    Betteridge DJ; Close L
    Eur Heart J; 2000 May; 21(10):790-2. PubMed ID: 10781346
    [No Abstract]   [Full Text] [Related]  

  • 4. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 5. [Differential therapy using oral antidiabetics].
    Mehnert H
    Internist (Berl); 1971 Nov; 12(11):468-75. PubMed ID: 4943878
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical trial of glypizide].
    Cañadell Vidal J
    Rev Iber Endocrinol; 1974 Jan; 21(121):61-73. PubMed ID: 4826383
    [No Abstract]   [Full Text] [Related]  

  • 7. Sulphonylureas, magnesium and cardiac K+ ATP channels.
    Matz R
    Diabetologia; 2000 Aug; 43(8):1080-1. PubMed ID: 10990091
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 9. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 10. Vascular disease in diabetes and the effect of oral antidiabetic agents.
    Marble A
    Adv Metab Disord; 1973; 2():Suppl 2:539-47. PubMed ID: 4720384
    [No Abstract]   [Full Text] [Related]  

  • 11. Controversies in management of diabetes in patients with coronary heart disease.
    Abdella NA
    Med Princ Pract; 2002; 11 Suppl 2():69-74. PubMed ID: 12444313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
    Blickle JF; Brogard JM
    Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
    [No Abstract]   [Full Text] [Related]  

  • 15. [Oral antidiabetic agents including glucosidase inhibitors].
    Raptis S
    Internist (Berl); 1987 Apr; 28(4):243-53. PubMed ID: 3298124
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long term efficacy and tolerance of antidiabetic treatments. New data].
    Mirouze J
    Nouv Presse Med; 1974 Jun; 3(24):1551-4. PubMed ID: 4211493
    [No Abstract]   [Full Text] [Related]  

  • 17. [The real problem in diabetes (trial of gliclazide, an original molecule with metabolic and vascular properties)].
    Masbernard A; Portal A
    Therapeutique; 1972 Nov; 48(9):569-73. PubMed ID: 4650526
    [No Abstract]   [Full Text] [Related]  

  • 18. [Study on Gliclazide, an antidiabetic with a double vascular and metabolic polarity].
    Simonin R
    Mars Med; 1972; 109(10):655-8. PubMed ID: 4659845
    [No Abstract]   [Full Text] [Related]  

  • 19. A diabetic woman with worsening heart failure, hunger, and tremor.
    Skugor M; Siraj ES
    Cleve Clin J Med; 2003 Oct; 70(10):882-8. PubMed ID: 14621233
    [No Abstract]   [Full Text] [Related]  

  • 20. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.